Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy
Shots:
- The US FDA has cleared IND application of ST-503 to initiate its P-I/II clinical evaluation to treat intractable pain due to idiopathic small fiber neuropathy
- The P-I/II trial will assess safety, tolerability & efficacy of ST-503 (intrathecal) to treat intractable pain from iSFN, a peripheral neuropathy causing severe pain symptoms, with the patient recruitment planned during mid-2025
- ST-503 uses an AAV vector with a zinc finger repressor to target SCN9A, encoding the Nav1.7 sodium channel. It has selectively reduced Nav1.7 expression in sensory neurons, significantly reducing pain hypersensitivity in animal models after a single intrathecal dose. It was well-tolerated in nonhuman primates without off-target effects
Ref: Sangamo Image: Sangamo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
